Alhemo (Concizumab)
Out of stock
We will notify you as soon as it becomes available.
-
Description
-
Related Products
-
Related Conditions
Fact Table
| Fact Table | |
|---|---|
| Formula | C6476H9972N1728O2048S52 |
| License | FDA Approved |
| Bioavailability | Not Available |
| Legal status | Prescription Only |
| Chemical Name | Concizumab |
| Elimination half-life | Approx. 19 days |
| Dosage (Strength) | 30 mg/ml injection |
| Pregnancy | Use with Caution |
| Brands | Alhemo |
| Protein binding | Unknown |
| PubChem CID | Not Available |
| MedlinePlus | Not Listed |
| ChEBI | Not Available |
| ATC code | B02BD14 |
| DrugBank | Not Available |
| KEGG | Not Available |
| Routes of administration | Subcutaneous |
Alhemo, also known as concizumab, is a biological treatment for hemophilia B, a blood disorder characterized by improper clotting leading to excessive bleeding. Symptoms of this condition can include unexplained bleeding, blood in the urine or stool, large or deep bruises, and indications of severe bleeds.
Alhemo functions by binding to the protein TFPI, which normally inhibits excessive blood clot formation. By binding to TFPI, Alhemo blocks its function, thereby enhancing blood clotting and reducing excessive bleeding. Before you buy Concizumab novo nordisk, it is crucial that you talk to your healthcare provider about its potential side effects and effectiveness.
Directions
Alhemo is available in the following dosages:
- 15 mg
- 60 mg
- 150 mg
- 300 mg
The medication is administered according to a schedule determined by your doctor. After four weeks of treatment, your doctor will assess Alhemo levels in your blood and adjust the dosage as necessary.
Ingredients
The active component of Alhemo is concizumab.
Cautions
Alhemo concizumab may lead to serious blood clots, potentially causing permanent damage or death. Inform your doctor if you have a personal or family history of blood clots. Ensure your doctor or pharmacist explains the signs and symptoms of blood clots and monitors you during treatment.
Alhemo is not recommended for patients under 12 years old or for use during pregnancy. If there is a possibility of becoming pregnant while on Alhemo, use effective birth control during treatment and for seven weeks after completion. If you miss a dose, consult your doctor or pharmacist for guidance.
Interactions
Common interactions with Alhemo include:
Activated prothrombin complex concentrates (PCC)
Recombinant FVIIa (rFVIIa)
rFVIII
rFVIX
Side Effects
Common side effects of Alhemo include:
- Allergic reactions (hypersensitivity)
- Blood clots
- Fever
- Headache
- Increased levels of blood clotting components (fibrin D dimer and prothrombin fragment 1.2)
- Infections
Frequently Asked Questions about Concizumab
What is concizumab?
Concizumab is a monoclonal antibody used in the treatment of hemophilia. It is designed to prevent bleeding episodes in patients with hemophilia A and hemophilia B, particularly those who have developed inhibitors against factor VIII or IX, which are standard treatments for these conditions.
What is the mechanism of action of concizumab?
The mechanism of action of concizumab involves binding to tissue factor pathway inhibitor (TFPI). By inhibiting TFPI, concizumab enhances the generation of thrombin, which is crucial for blood clot formation. This helps to control bleeding in hemophilia patients, even in the presence of inhibitors to standard treatments.
What is the route of administration for concizumab?
Concizumab is administered via subcutaneous injection. This route allows the medication to be absorbed slowly and steadily into the bloodstream, providing sustained therapeutic effects.
What is the half-life of concizumab?
The half-life of concizumab varies based on individual patient factors but typically ranges from 14 to 26 days. This relatively long half-life supports less frequent dosing schedules, which can be advantageous for patient compliance and convenience.
How does concizumab work?
Concizumab works by inhibiting tissue factor pathway inhibitor (TFPI). By blocking TFPI, concizumab promotes the generation of thrombin, an enzyme essential for blood clotting. This action helps to prevent and control bleeding episodes in patients with hemophilia, particularly those with inhibitors to factor VIII or IX.
